Department of Anesthesiology, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire 03756, USA.
Anesthesiology. 2010 Jun;112(6):1335-44. doi: 10.1097/ALN.0b013e3181d3d7f6.
Propofol is the anesthetic of choice for patients with reactive airway disease and is thought to reduce intubation- or irritant-induced bronchoconstriction by decreasing the cholinergic component of vagal nerve activation. However, additional neurotransmitters, including neurokinins, play a role in irritant-induced bronchoconstriction. We questioned the mechanistic assumption that the clinically recognized protective effect of propofol against irritant-induced bronchoconstriction during intubation was due to attenuation of airway cholinergic reflexes.
Muscle force was continuously recorded from isolated guinea pig tracheal rings in organ baths. Rings were subjected to exogenous contractile agonists (acetylcholine, histamine, endothelin-1, substance P, acetyl-substance P, and neurokinin A) or to electrical field stimulation (EFS) to differentiate cholinergic or nonadrenergic, noncholinergic nerve-mediated contraction with or without cumulatively increasing concentrations of propofol, thiopental, etomidate, or ketamine.
Propofol did not attenuate the cholinergic component of EFS-induced contraction at clinically relevant concentrations. In contrast, propofol relaxed nonadrenergic, noncholinergic-mediated EFS contraction at concentrations within the clinical range (20-100 mum, n = 9; P < 0.05), and propofol was more potent against an exogenous selective neurokinin-2 receptor versus neurokinin-1 receptor agonist contraction (n = 6, P < 0.001).
Propofol, at clinically relevant concentrations, relaxes airway smooth muscle contracted by nonadrenergic, noncholinergic-mediated EFS and exogenous neurokinins but not contractions elicited by the cholinergic component of EFS. These findings suggest that the mechanism of protective effects of propofol against irritant-induced bronchoconstriction involves attenuation of tachykinins released from nonadrenergic, noncholinergic nerves acting at neurokinin-2 receptors on airway smooth muscle.
异丙酚是气道反应性疾病患者的首选麻醉剂,据认为通过减少迷走神经激活的胆碱能成分,可减少插管或刺激性诱导的支气管收缩。然而,包括神经激肽在内的其他神经递质在刺激性诱导的支气管收缩中起作用。我们质疑这样一个机制假设,即异丙酚在插管期间对刺激性诱导的支气管收缩的临床公认的保护作用归因于气道胆碱能反射的衰减。
在器官浴中连续记录分离的豚鼠气管环的肌肉力。环接受外源性收缩性激动剂(乙酰胆碱、组胺、内皮素-1、P 物质、乙酰-P 物质和神经激肽 A)或电刺激(EFS),以区分胆碱能或非肾上腺素能、非胆碱能神经介导的收缩,同时有无累积增加的异丙酚、硫喷妥钠、依托咪酯或氯胺酮浓度。
异丙酚在临床相关浓度下并未减弱 EFS 诱导收缩的胆碱能成分。相比之下,异丙酚在临床范围内的浓度(20-100 mum,n = 9;P < 0.05)下舒张非肾上腺素能、非胆碱能介导的 EFS 收缩,且异丙酚对选择性神经激肽-2 受体的作用比对神经激肽-1 受体激动剂收缩更强(n = 6,P < 0.001)。
在临床相关浓度下,异丙酚舒张由非肾上腺素能、非胆碱能介导的 EFS 和外源性神经激肽引起的气道平滑肌收缩,但不舒张 EFS 胆碱能成分引起的收缩。这些发现表明,异丙酚对刺激性诱导的支气管收缩的保护作用机制涉及到对非肾上腺素能、非胆碱能神经释放的作用于气道平滑肌神经激肽-2 受体的速激肽的衰减。